NAPLEX LUNG CANCER TREATMENT EXAM 2025 | 98 QUESTIONS
WITH ACCURATE SOLUTIONS
1. Which of the following is the most appropriate premedication regimen for
docetaxel?
Ondansetron 8mg IV 30 minutes prior, mesna during and after the
infusion, dexamethasone 12 hours before, 6 hours before, and 30
minutes before docetaxel
Dexamethasone 20mg 12 hours before, diphenhydramine,
cimetidine, and dexamethasone 30 minutes before infusion
Filgrastim 5 ucg/kg sq 24 hours after, dexamethasone 12mg 30
minutes prior to chemotherapy
Dexamethasone 4mg PO bid day before, day of, and day after
chemotherapy
2. Explain why Citalopram is contraindicated for patients undergoing
treatment with osimertinib. What specific risk does this combination pose?
It may cause severe allergic reactions.
It can lead to increased blood pressure.
Both drugs can prolong the QT interval, increasing the risk of
serious heart arrhythmias.
It may reduce the effectiveness of osimertinib.
3. What is the brand name of crizotinib?
Xalkori
,Opdivo
Cyramza
Iressa
,4. A 66-year-old female patient with relapsed small cell lung cancer asks you
about the best available second-line treatment. Which medication will you
recommend?
Topotecan
Pemetrexed
Bevacizumab
Vinorelbine
5. A patient with lung cancer has been found to have an ALK gene mutation.
Which of the following treatment options would be most appropriate for
this patient?
Xalkori (crizotinib)
Opdivo (nivolumab)
Cyramza (ramucirumab)
Iressa (gefitinib)
6. Explain why the dosing of pembrolizumab is standardized at 200 mg every
3 weeks for most indications in NSCLC treatment.
It is based on clinical trials showing efficacy and safety.
It is the maximum dose allowed for all cancer treatments.
It is the only dosing regimen available for pembrolizumab.
It is determined by the patient's weight and age.
7. Explain the difference in mechanism of action between Ramucirumab and
, Bevacizumab in the treatment of lung cancer.
Ramucirumab binds to circulating VEGF, while Bevacizumab binds to
the VEGF receptor.
Ramucirumab binds to the VEGF receptor, whereas Bevacizumab
binds to circulating VEGF.
WITH ACCURATE SOLUTIONS
1. Which of the following is the most appropriate premedication regimen for
docetaxel?
Ondansetron 8mg IV 30 minutes prior, mesna during and after the
infusion, dexamethasone 12 hours before, 6 hours before, and 30
minutes before docetaxel
Dexamethasone 20mg 12 hours before, diphenhydramine,
cimetidine, and dexamethasone 30 minutes before infusion
Filgrastim 5 ucg/kg sq 24 hours after, dexamethasone 12mg 30
minutes prior to chemotherapy
Dexamethasone 4mg PO bid day before, day of, and day after
chemotherapy
2. Explain why Citalopram is contraindicated for patients undergoing
treatment with osimertinib. What specific risk does this combination pose?
It may cause severe allergic reactions.
It can lead to increased blood pressure.
Both drugs can prolong the QT interval, increasing the risk of
serious heart arrhythmias.
It may reduce the effectiveness of osimertinib.
3. What is the brand name of crizotinib?
Xalkori
,Opdivo
Cyramza
Iressa
,4. A 66-year-old female patient with relapsed small cell lung cancer asks you
about the best available second-line treatment. Which medication will you
recommend?
Topotecan
Pemetrexed
Bevacizumab
Vinorelbine
5. A patient with lung cancer has been found to have an ALK gene mutation.
Which of the following treatment options would be most appropriate for
this patient?
Xalkori (crizotinib)
Opdivo (nivolumab)
Cyramza (ramucirumab)
Iressa (gefitinib)
6. Explain why the dosing of pembrolizumab is standardized at 200 mg every
3 weeks for most indications in NSCLC treatment.
It is based on clinical trials showing efficacy and safety.
It is the maximum dose allowed for all cancer treatments.
It is the only dosing regimen available for pembrolizumab.
It is determined by the patient's weight and age.
7. Explain the difference in mechanism of action between Ramucirumab and
, Bevacizumab in the treatment of lung cancer.
Ramucirumab binds to circulating VEGF, while Bevacizumab binds to
the VEGF receptor.
Ramucirumab binds to the VEGF receptor, whereas Bevacizumab
binds to circulating VEGF.
